EPZM News and Press, Epizyme Inc. From 08/08/21

Collaboration designed to accelerate global development and investigate TAZVERIK ® combinations with HUTCHMED’s novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, togethe...

AMRX,APD,AVYA,BALY,BHVN,BLUE,BNTX,CEVA,CRNC,DISH,EBIX,ELAN,ENR,EPZM,GOLD,GTES,KOD,RDNT,SGMS,SWAV,SYNH,TGNA,TSN,TTD,USFD,VTRS,VTR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its second quarter 2021 financial results and provide a business upda...

Epizyme Inc. (NASDAQ:EPZM) traded today at a new 52-week low of $6.49. Approximately 105,000 shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares. In the past 52 weeks, Epizyme Inc. share prices are bracketed by a current low of $6.49 and a high ...

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

Shares of biotech Epizyme (NASDAQ: EPZM) have been a bit sickly this week, following the departure of one of its top executives. As of Thursday's market close, the stock was down nearly 13% from the start of the week. The outgoing executive is CFO Paolo Tombesi, whom Epizyme ann...

JuSun/iStock via Getty Images During the week ended June 25, 2021, Healthcare sector rose 2.01% and Healthcare Select Sector SPDR ETF (XLV) gained 1.58% compared to weekly gain of 2.82% of S&P 500 ETF. Leading the top gainers pack was Atossa Therapeutics (ATO...

Today, we revisit Epizyme for the first time since early this year. The company's flagship product was approved in 2020 for two indications and it is focused on ramping up sales and moving other enabling studies forward. A full investment analysis follows in the paragraphs below. ...

Epizyme continues to advance its confirmatory studies to keep TAZVERIK on the market for treating patients with epithelioid sarcoma and follicular lymphoma. Sales of TAZVERIK were low at $6.2 million for Q1 2021, but may be due to the COVID-19 environment which hampered sales. Expande...

EZH2Now Testing Program is first of its kind to offer national single gene testing for EZH2 Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched the EZH2Now Testing Progr...